Larimar Therapeutics
LRMR
Market cap $495M

7.76 USD

-0.09

1.15%

At close Oct 18, 4:00 PM EDT

After hours

7.77

+0.01

0.13%

1 day

-1.15%

5 days

11.02%

1 month

13.28%

3 months

-16.83%

6 months

21.63%

Year to date

51.86%

1 year

157.81%

5 years

-36.91%

About: Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using novel cell-penetrating peptide technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.

Employees: 42

Healthcare Pharmaceutical Preparations

0

Funds holding %

of 6,740 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

905% more call options, than puts

Call options by funds: $3.3M | Put options by funds: $328K

15% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 34

14% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 21

3% more funds holding

Funds holding: 103 [Q1] → 106 (+3) [Q2]

2.62% more ownership

Funds ownership: 99.75% [Q1] → 102.38% (+2.62%) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]

2% less capital invested

Capital invested by funds: $483M [Q1] → $473M (-$9.55M) [Q2]

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$14

80%

upside

Avg. target

$18.60

140%

upside

High target

$26

235%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

Oppenheimer Andreas Argyrides 66% 1-year accuracy 23 / 35 met price target	235%upside $26	Outperform Initiated	16 Oct 2024
Wedbush Laura Chico 57% 1-year accuracy 41 / 72 met price target	184%upside $22	Outperform Initiated	3 Oct 2024
HC Wainwright & Co. Edward White 30% 1-year accuracy 37 / 125 met price target	93%upside $15	Buy Initiated	2 Oct 2024
Jones Trading Catherine Novack 20% 1-year accuracy 1 / 5 met price target	80%upside $14	Buy Initiated	12 Sept 2024
Baird Joel Beatty 56% 1-year accuracy 19 / 34 met price target	106%upside $16	Outperform Initiated	4 Sept 2024

See Analyst Rankings

Financial journalist opinion

Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock

Oppenheimer has initiated coverage on Larimar Therapeutics LRMR, a clinical-stage biotechnology company focused on developing treatments for rare diseases.

Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Larimar Therapeutics' CTI-1601, a potential first-in-class treatment for Friedreich's ataxia, shows promise in modifying disease progression and restoring mitochondrial function. The company has a solid cash runway, sufficient liquidity, and trades at reasonable valuations compared to its upside potential. LRMR's favorable Phase 1/2 trial results bolster CTI-1601's approval odds, with a potential Biologics License Application submission by 2H2025.

Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential

Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research

BALA CYNWYD, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company's nomlabofusp Phase 1 studies and Phase 2 dose exploration study, some of which has been previously disclosed, will be presented at the annual International Congress for Ataxia Research (ICAR) being held November 12-15, 2024 in London, U.K. Nomlabofusp is a novel protein replacement therapy designed to address the root cause of Friedreich's ataxia by delivering frataxin to mitochondria.

Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

Partial clinical hold from FDA, for use of nomlabofusp for the treatment of patients with Friedreich's Ataxia completely lifted; higher dosing of 50 mg of treatment now possible. It is expected that the global Friedreich's Ataxia market could reach $2.06 billion by 2030. Interim data from the ongoing phase 2 open-label study, using nomlabofusp for the treatment of patients with Friedreich's Ataxia, expected Q4 of 2024.

Larimar: Stronger Buy Now More Than Ever After Partial Clinical Hold Completely Removed

Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia

BALA CYNWYD, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the United States Food and Drug Administration (FDA) has selected nomlabofusp to participate in the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program. Nomlabofusp is a novel protein replacement therapy designed to address the root cause of Friedreich's ataxia (FA) by delivering frataxin to mitochondria. START selection was based on demonstrated development program readiness, including the potential of nomlabofusp to address the serious and unmet medical needs in a rare neurodegenerative condition, alignment of chemistry, manufacturing, and controls (CMC) development timelines with clinical development plans, and a proposed communications plan where enhanced communication could accelerate pivotal study initiation and path to potential Biologics License Application (BLA) submission.

Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia

The Motley Fool

2 Potentially High-Reward Growth Stocks to Buy Right Now

Growth stocks have been the U.S. market's primary value driver since 2008. Biotechnology equities, however, have been in a wilderness period since the central bank ramped up interest rates.

2 Potentially High-Reward Growth Stocks to Buy Right Now

Zacks Investment Research

Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study

The FDA removes the partial clinical hold on Larimar's (LRMR) nomlabofusp clinical program for the treatment of patients with Friedreich's Ataxia.

Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study

Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia

BALA CYNWYD, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the U.S. FDA has removed the partial clinical hold previously placed on the company's nomlabofusp (CTI-1601) clinical program. Nomlabofusp is currently in development for the treatment of patients with Friedreich's Ataxia (FA). Nomlabofusp is a novel protein replacement therapy designed to address the root cause of FA by delivering frataxin to mitochondria. The FDA removed the partial clinical hold after a review of data from the Company's recently completed four-week, placebo-controlled Phase 2 dose exploration study. The review included data from both the 25 mg and 50 mg cohorts in patients who received daily dosing of nomlabofusp for 14 days followed by every other day dosing until day 28.

Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia

Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results

BALA CYNWYD, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its first quarter 2024 operating and financial results.

Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

BALA CYNWYD, Pa., March 14, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its fourth quarter and full year 2023 operating and financial results.

Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development

See News Rankings

Charts implemented using Lightweight Charts™